tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

KNSA Stock Latest News

Kiniksa price target raised to $55 from $45 at Goldman Sachs
The FlyKiniksa price target raised to $55 from $45 at Goldman Sachs
16d ago
KNSA
Kiniksa Pharmaceuticals Reports Strong Q3 2025 Growth
PremiumCompany Announcements
Kiniksa Pharmaceuticals Reports Strong Q3 2025 Growth
17d ago
KNSA
Kiniksa Pharmaceuticals’ Earnings Call Highlights Growth and Optimism
PremiumCompany Announcements
Kiniksa Pharmaceuticals’ Earnings Call Highlights Growth and Optimism
17d ago
KNSA
Kiniksa Pharmaceuticals: Strong Q3 Performance and Growth Potential Justify Buy Rating
PremiumRatings
Kiniksa Pharmaceuticals: Strong Q3 Performance and Growth Potential Justify Buy Rating
17d ago
KNSA
Kiniksa riases FY25 ARCALYST net product revenue view $670M-$675M
PremiumThe Fly
Kiniksa riases FY25 ARCALYST net product revenue view $670M-$675M
17d ago
KNSA
Kiniksa expects current operating plan to remain cash flow positive
PremiumThe FlyKiniksa expects current operating plan to remain cash flow positive
17d ago
KNSA
Kiniksa reports Q3 EPS 23c, consensus 37c
Premium
The Fly
Kiniksa reports Q3 EPS 23c, consensus 37c
17d ago
KNSA
Kiniksa Pharmaceuticals’ Promising Study on KPL-387 for Recurrent Pericarditis
Premium
Company Announcements
Kiniksa Pharmaceuticals’ Promising Study on KPL-387 for Recurrent Pericarditis
18d ago
KNSA
KNSA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
KNSA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
19d ago
KNSA
Strong Commercial Execution and Growth Potential Drive Buy Rating for Kiniksa Pharmaceuticals
PremiumRatings
Strong Commercial Execution and Growth Potential Drive Buy Rating for Kiniksa Pharmaceuticals
24d ago
KNSA
Kiniksa announces Orphan Drug Designation for KPL-387
PremiumThe Fly
Kiniksa announces Orphan Drug Designation for KPL-387
28d ago
KNSA
Kiniksa price target raised to $50 from $45 at Citi
PremiumThe Fly
Kiniksa price target raised to $50 from $45 at Citi
28d ago
KNSA
Kiniksa granted orphan designation for treatment of pericarditis
PremiumThe FlyKiniksa granted orphan designation for treatment of pericarditis
29d ago
KNSA
Kiniksa price target raised to $44 from $38 at Wedbush
Premium
The Fly
Kiniksa price target raised to $44 from $38 at Wedbush
1M ago
KNSA
Kiniksa Pharmaceuticals: Strong Buy Rating Driven by Arcalyst’s Market Success and Promising Pipeline
Premium
Ratings
Kiniksa Pharmaceuticals: Strong Buy Rating Driven by Arcalyst’s Market Success and Promising Pipeline
2M ago
KNSA
Kiniksa initiated with a Buy at TD Cowen
PremiumThe Fly
Kiniksa initiated with a Buy at TD Cowen
2M ago
KNSA
Kiniksa Pharmaceuticals Highlights Cardiovascular Focus and Growth
PremiumCompany Announcements
Kiniksa Pharmaceuticals Highlights Cardiovascular Focus and Growth
2M ago
8K
KNSA
Kiniksa Pharmaceuticals Reports Strong Q2 2025 Growth
PremiumCompany Announcements
Kiniksa Pharmaceuticals Reports Strong Q2 2025 Growth
4M ago
KNSA
Kiniksa Pharmaceuticals Reports Strong ARCALYST Growth
PremiumCompany Announcements
Kiniksa Pharmaceuticals Reports Strong ARCALYST Growth
4M ago
KNSA
Kiniksa price target raised to $54 from $45 at Jefferies
PremiumThe FlyKiniksa price target raised to $54 from $45 at Jefferies
4M ago
KNSA
Kiniksa reports Q2 EPS 23c, consensus 26c
Premium
The Fly
Kiniksa reports Q2 EPS 23c, consensus 26c
4M ago
KNSA
Kiniksa raises FY25 ARCALYST revenue view to $625M-$640M from $590M-$605M
Premium
The Fly
Kiniksa raises FY25 ARCALYST revenue view to $625M-$640M from $590M-$605M
4M ago
KNSA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >